Infex Awarded Biomedical Catalyst Grant For COV-X Project

Alderley Park, Cheshire, U.K - Infex Therapeutics, a leading anti-infectives…


Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism

Alderley Park, Cheshire - Infex Therapeutics, one of the UK’s leading…


Infex scientists achieve breakthrough to overcome critical priority drug resistant infections

Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…


Infex agrees partnership with Colibri Scientific to provide services for RESP-X program

Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…


Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains

Alderley Park, Cheshire –  One of the UK’s leading infectious disease biotech…


Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics

Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr…


Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership

Alderley Park, Cheshire - Infex Therapeutics is pressing ahead with a major…


Tackling underlying respiratory conditions for this pandemic and next

During the COVID-19 pandemic, one of the many phrases that has become…


Infex appoints Lonza to manufacture new lung infection drug

Alderley Park, Cheshire Infex Therapeutics has awarded a £1m contract to Lonza…